Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

09/24/2021 | 07:04am EDT

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a late-breaking presentation of preliminary clinical data from the on-going 4D-125 Phase 1/2 trial in patients with X-Linked Retinitis Pigmentosa (XLRP) will be presented at the upcoming Annual Society of Retina Specialists Annual Meeting (ASRS) 2021 that will take place in San Antonio, TX on October 8-12, 2021.

Details of the ASRS presentation are as follows:

Title: Phase 1/2 Clinical Trial of Intravitreal 4D-125 AAV Gene Therapy in Patients with Advanced XLRP: Interim Safety & Preliminary Activity

Speaker: Dr. Cagri G. Besirli M.D., Ph.D, Kellogg Eye Center, University of Michigan

Session: Surgical Techniques & Maneuvers Symposium (Late Breaker Acceptance)

Date and Time: Sunday, October 10, 2:56 p.m. CDT

The presentation will be available for viewing by registered participants during the conference via the ASRS mobile meeting website on October 10, 2021.

About the 4D-125 Phase 1/2 Clinical Trial

4DMT is currently enrolling patients in an on-going Phase 1/2 dose-escalation and dose-expansion clinical trial assessing intravitreal 4D-125, 4DMT’s targeted and evolved R100-based product candidate for XLRP. The study employs a standard 3+3 dose-escalation design, followed by dose expansion. Patients are enrolled in one of two dose cohorts: 3E11 vg/eye and 1E12 vg/eye. The dose expansion phase of the study is enrolling patients at the 1E12 vg/eye dose. The primary objectives of this trial are to evaluate the safety and maximum tolerated dose of 4D-125. Secondary endpoints include assessments of clinical activity, including both visual field function and anatomical endpoints.

About XLRP

XLRP is a rare inherited X-linked recessive genetic disorder that causes progressive vision loss and blindness in boys and young men. There are currently no approved therapies for XLRP. Seventy percent of cases are caused by mutations in the retinitis pigmentosa GTPase regulator (“RPGR”) gene. The estimated worldwide prevalence of XLRP due to RPGR variants is approximately one in 25,600 people, which represents approximately 24,000 patients in the United States, and France, Germany, Italy, Spain and the United Kingdom (together, EU-5). It is characterized by dysfunction and degeneration of photoreceptors in the retina. Symptoms of XLRP are initially characterized by night blindness, followed by loss of peripheral visual field, decreasing visual acuity and eventually blindness.

About 4DMT

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.

4D-310, 4D-125 and 4D-110 are our product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of 4D-310, 4D-125, or 4D-110 for the therapeutic use for which they are being studied.

4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.



Carolyne Zimmermann
Chief Business Officer


Mike Zanoni
VP, Investor Relations

Primary Logo

© GlobeNewswire 2021
10/134D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
10/114D MOLECULAR THERAPEUTICS' : 4D-125 Drug Shows Potential in Eye Disease Trial
10/104D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
10/104D MOLECULAR THERAPEUTICS : Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cli..
10/104D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cl..
10/06Health Care Stocks Trade Lower Premarket Wednesday
10/064D MOLECULAR THERAPEUTICS : Obtains FDA Clearance for Phase 1/2 Trial of Wet Age-Related M..
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-710, an A101..
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-150, a Dual-..
10/064D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual..
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Capitalization 806 M 806 M -
EV / Sales 2021 36,0x
EV / Sales 2022 234x
Nbr of Employees 104
Free-Float 77,1%
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 29,86 $
Average target price 50,00 $
Spread / Average Target 67,4%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.220.51%130 866
LONZA GROUP AG26.90%58 060
SEAGEN INC.-1.81%31 426
CELLTRION, INC.-39.69%25 414